Elon musk tesla truck

With Tesla operating (now big enough to join the Fortune 500 list for the first time), between SpaceX's leading rocket launch and launching other futuristic businesses, Elon Musk doesn't have much time. Musk, however, asked at Tesla's shareholder meeting Tuesday how he would relax after work. Having initially acknowledged that the after-hours schedule tends to work more,Musk said it's usually not normal to do things off the clock. Last weekend, for example, she saw the new hit film Wonder Woman with her children. (He was also recently photographed ziplining in Australia, and earlier this week tweeted while visiting the DMV.) After a moment of hesitation, however, the Tesla CEO added that he had other pastimes, or at least habits. Sometimes twitter goes crazy, he told shareholders at the meeting. yes, a little red wine, vintage turntable, a little ambien--magic! Magic is happening, he continued. (Ambien is an anesthesia medication that can be prescribed for insomnia; doctors recommend not to take it with alcohol.) A few hours later, he repeated the comments in a tweet. A little red wine, vintage record, some Ambien... and magic!— Elon Musk (@elonmusk) June 7, 2017Musk has assured Tesla shareholders that even if they often tweets from other companies, most of them take up very little of their time. Musk said he spends at least 90% of his time at the electric car factory or SpaceX; 3% to 5% of Neuralink, the company aims to create interfaces between the human brain and machine learning technology; 2% for its new tunnel project, the Boring Society; the remainder on OpenAI, a non-profit organisation dedicated to artificial intelligence research. I might tweet a lot about Boring Corporation, which is basically a hobby - I wouldn't call it a real company right now, musk said. Three people, some interns and some part-time. No pressure. Tesla, which in addition to developing self-driving cars could push solar power after acquiring SolarCity last year, tends to keep him the most busy, Musk added. Tesla is like a drama magnet, so they have to deal with the Tesla drama, he said. (For more on Tesla, see the new Fortune feature, Tesla takes it down in China.) Musk also hinted that he was working to improve the selection of songs available in Tesla cars, where he would rather listen to music, and that there would be exciting announcements later this year. According to Musk's description, the new offer was a bit like Spotify's potential competitor: I think it's very difficult to find good playlists and good match algorithms, Musk said. I think this job is really great. This is going to be the music you want to listen to. Well, at least I want to hear it. Which is another popular In the form of recreation, Musk (who grew up in South Africa) said it has little use for it: It may not shock, but sports aren't something you don't have much. See the original article on Fortune.comMore Fortune.com The withdrawal of Nikola continues. Today, the company announced the termination of the contract with Republic Services for 2,500 garbage trucks. Announced back in August, the deal was nikola building garbage trucks in 2023 for a road test scheduled for 2024.The $900 billion coronavirus relief deal includes six tax breaks for Americans. Three more tax breaks will appear on the government's spending bill attached to the package. The president wants $2,000, not $600. What can you do? Can you feel the earth moving under your feet? Shares of Ocugen (OCGN) have skyrocketed more than 800% in the past three trading sessions after the biopharmaceous company disclosed that it had signed a mandatory letter of intent (LOI) with India-based Bharat Biotech to jointly develop a COVID-19 vaccine for the U.S. market. Bharat offers COVAXIN, a whole vironin-activated COVID-19 vaccine candidate, has been shown promising in phase 1 and 2 clinical trials in India and enrollment of 26,000 subjects in the Phase 3 trial is currently underway. The agreement states Ocugen will keep the vaccine's U.S. rights, and the remaining details are expected to be finalized in the coming weeks. Considering Bharat's reputation for world-class R&D and manufacturing capabilities in vaccines and bio-therapy, H.C. Wainwright analyst Swayampakula Ramakanth thinks the company is a suitable partner. Ramakanth believes that a wide range of immunity targeting various components of the virus could potentially provide better protection against emerging mutated viruses, such as the virus currently circulating in the UK. With this in mind, in the Phase 1 study, COVAXIN showed strong antibody responses against the nucleocaine (N) protein of the spike (S1) protein, receptor binding domain (RBD) and SARS-CoV-2. More importantly, the 5-star analyst added COVAXIN also indues similar levels of neutralizing antibodies to those in human convalescing serum, which, the analyst believes, is a good omen for success in the ongoing Phase 3 trial in India. In the coming weeks, Ocugen is expected to meet with the FDA to discuss how to advance COVAXIN development. However, due to the fact that the details of the final agreement have not yet been finalized, in addition to the current lack of insight into the U.S. regulatory path or trade strategy, Ramakanth remains on the sidelines now. Accordingly, the analyst assesses OCGN as neutral (i.e. moon) without proposing a price target. (To watch Ramakanth's past, click here) By contrast, all 3 other analysts who recently posted an Ocugen rate of stock in buy. However, Strong Buy Buy rating is supported with a $0.9 price target, which means suspecting by low of 68% of current levels. This is likely a result of the stock rising meteorically and analysts not being able to target new price targets so quickly. (See OCGN inventory analysis at TipRanks) To find good ideas for coronavirus stocks trading with attractive valuations, visit TipRanks' Best Stocks buy, a newly launched tool that combines all of TipRanks equity insights. Disclaimer: The opinions in this article are exclusively those of the featured analysts. The content is for informational use only. It is very important to do your own analysis before making any investment. Los Angeles-based startup Canoo's executive chairman said Apple's electric car news had a ripple effect on the EV space. Ethereum (ETH) is the second largest cryptocurrency in terms of market capitalization after bitcoin (BTC). It was released on July 30, 2015 with original authors Vitalik Buterin and Gavin Wood. So, how has this altcoin fared over the past half decade? Ethereal Highs: Assuming an investor bought $1,000 worth of ETH on December 23, 2015, they would have picked up 1,162.79 units at a price of around $0.86. Fast forward just three years to January 13, 2018, when ETH hit an all-time high of 1,432.88 and that $1,000 investment would have turned into $1.67 million. Five years later press time, and $1,000 would be worth $709,740.70. Yields may not be as impressive as 2018, but they still make a whopping 70.974% profit. Even for the earliest ETH investors, the cryptocurrency unleashed a bonanza return of 21,971.12%. The earliest known price of the ETH is $2.77, which on December 23, 2015 was $1,000 for about $2.29 bitcoin, which would be worth nearly $52,956 in press time. On the share side, investors in Tesla Inc (NASDAQ: TSLA), Amazon.com, Inc (NASDAQ: AMZN) and Apple Inc (NASDAQ: AAPL) would have enjoyed a return of 1,278.85%, 2,450.02% and 391.72%. Price Action: ETH traded 2.17% higher at $617.13 in press-time, while BTC traded 3.54% higher at $23,589.53.On Tuesday, Grayscale Ethereum Trust (OTC: ETHE) closed 7.64% higher at $23.40 and Grayscale Bitcoin Trust (OTC: GBTC) closed 1.43% lower at $30.39.See more about Benzinga* Click here for options trades in the Benzinga*SEC rule change as direct listings undoubtedly spells the endgame of traditional IPO's , says Bill Gurley * AstraZeneca to test the COVID-19 vaccine in combination with Russia's Sputnik V(C) by 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. In 2000, while everything was about Qualcomm QCOM, Intel INTC, an assortment Dot-com kits were doomed. Two decades later, and players have changed, but the stock story rings familiar, according to Luke Palmer of the popular Bear Traps Report blog. Moderna (MRNA) shareholders have exited the exits at an aggressive pace over the past four weeks. The conventional wisdom is that we are on the cusp of another major stock market rally. 2020 was a volatile year, with an unprecedented coronavirus recession in February and March, followed by a bull running through the summer and fall, with increased volatility late in the fall as investors tried to understand the election and the second wave of the virus. But that's all in the past. With the election settled, Congress is so narrowly divided that major legislative initiatives are unlikely and long-awaited COVID vaccines are starting to enter circulation. In short, there is a combination of risk and reward creation, investors are willing to get some skin in the game. And for those who are really ready to shoulder the extra risk, penny stocks may be the right choice for a big rally. These stocks are priced low, below $5 per share, and low prices usually happen for a good reason. But a few penny stocks are basically healthy, and the low price has been baked to have nowhere else to go but up. Using the TipRanks database, we picked up data from two impressive stocks that fit the profile of a low share price and huge upside potential, 200% or more, according to Wall Street analysts. Not to mention, both boast a Strong Buy consensus rating. Palatin Technologies (PTN)Let's start with Palatin Technologies, a biopharma products company with a unique niche and competitive edge. Palatin specializes in the development of melanocortin and natriuretic peptide receptor systems. These are a new class of potential drugs, receptor-specific and targeted toward specific diseases. Palatine drugs develop dry eye disease, obesity, and congestive heart failure. Palatin pipeline has more immediate applications as well - PL8177, originally a target for ulcerative colitis, recently entered Phase 1 trials as a treatment for covid-19. The competitive advantage, Palatin vyleesi. Vyleesi is the marketing brand name bremelanotide, the first melanocortin peptide treatment for premenopausal women with generalized hypoactive sexual desire disorder. The FDA considers Vyleesi a first-class medication and has approved it for June 2019. Palatin has since marketed Vyleesi in North America. In July of this year, Palatin settled a legal dispute with AMAG Pharmaceutical in which Palatin regained all North American rights to Vyleesi, as well as a $16.3 million settlement, of which $12 million had already been paid. Currently going for $0.42 apiece, Canaccord analyst John considers that the share price is an attractive entry point. Vyleesi continues to make commercial progress, ensuring broader insurance reimbursement coverage and strengthening relationships with health care providers [...] Palatin continues to look for potential U.S. reauthorization of Vyleesi to enhance commercialization. Possible re-licensing/partnership revolves around a company currently in the women's health products market. We believe that a new re-licensing agreement could carry a meaningful upfront payment, given that Vyleesi has full FDA approval, the 5-star analyst opined. In addition, Palatin announced Phase 2 data from the PL9643 Dry Eye Disease (DED) exploratory study last week. Newman points out that the results showed statistically significant improvements in multiple signs and symptoms in the moderate to severe patient population. Palatin plans to begin phase 2/3 trials in mid-2021. In keeping with his bullish stance, Newman rates PTN at Buy, and his $3 price target means room for a whooping cough is 615% upside possible in the next 12 months. (Click here to see Newman's past) Overall, Palatin receives a Strong Buy rating from the analyst consensus and that verdict is unanimous, based on 3 recent Buy reviews. The average price target, $2.17, means an impressive 417% upside for next year. (See PTN file analysis of TIPRangs) Mustang Bio (MBIO)Mustang Bio is another clinical phase biopharmacistric company. Mustang is the focus of possible cures for blood cancer, solid tumors, and genetic diseases, medical breakthroughs in cell and gene therapies to create targeted drugs. The company is actively developing CAR-T (Chimera antigen receptor T cells) therapies for the treatment of non-Hodgkin leukemia and other cancers. Mustang is a robust research pipeline, with gene therapies, hematological CAR-Ts, and solid tumor CAR-Ts under development to treat a number of diseases. Preclinical research is underway and by 2023 1. The company has six clinical trials underway, with conditions ranging from glioblastomas to multiple myeloma to prostate cancer. The company's clinical-stage drug, MB-106, shows promise as a treatment for non-Hodgkin Leukemia.In in a detailed review of the company's B. Riley Securities, analyst Justin Zelin notes, with the early success of MB-106, and the possibility that the company will go ahead. The MB-106 has an 89% total response rate (ORR) and a 44% total response rate (CRR) and a highly favorable safety profile in nhl patients treated with mustang's modified cell production process as a significantly positive risk anesthesion event for the program and the Mustang platform as a whole. In the footsteps of this positive data set, Mustang in 1Q21E submits an application for a new drug (IND) to allow Multicenter Phase II study mb-106, which is a de-risked registration pathway for approval of CD20+ NHL patients, Zelin wrote. On the bottom line, Zelin bullish on Mustang, writing: We continue to believe Mustang Bio is undervalued compared to its peers due to its historical lack of catalysts and clinical data, which is now changing to positive clinical data presentation. Zelin's comments return the Buy valuation, and his $13 price target marks room for up to 300% growth next year. (To watch Zelin's past, click here) Mustang is another penny stock with unanimous Strong Buy reviews, this is based on 4 recent Buy reviews. The company's stock is sold for $3.16, and the average price target is $10.75, suggesting a 235% upside price within the one-year timeframe. (See MBIO inventory analysis from TipRanks) To find good ideaspenny stocks trading attractive valuations, visit TipRanks' Best Stocks buy, a newly launched tool that combines all of TipRanks equity insights. Disclaimer: The opinions in this article are exclusively those of the featured analysts. The content is for informational use only. It is very important to do your own analysis before making any investment. Investor's Business DailyAlibaba stock is an IBD long-term leader in outstanding fundamentals, but does that make the Chinese bellwether a buy now? There's not a number. Exactly what you'll need for retirement and the time frame until the day and deduce what to expect from the 401 (k) of this. It's not easy to make a car. Even tech giant Apple.The $57,700 lunch turned out to be an excellent investment that led to a friendship and, finally, a business partnership. I think the enthusiasm for the tireless wave of these buyers is equal to or better than the despise of S&S; They're like professionals. You can inherit the IRA tax-free, but you can get a 50% penalty if you don't follow the minimum allocation (RMD) rules. Investor's Business DailySee, who joins PayPal, Veeva and Lululemon on this screen in Warren Buffett stocks, is based on the investment strategy of Berkshire Hathaway's CEO. The Grayscale Bitcoin Trust (GBTC) is a key definition of a correction in Bitcoin price, according to analysts at JPMorgan.Rosemary Vrablic, managing director and senior banker in the lender's asset management division, recently handed in her resignation, which the bank accepted as effective as the end of the year, Deutsche Bank spokeswoman Dan Hunter said in an emailed statement. According to the New York Times, which first reported vrablic's resignation, he arranged for the lender to lend hundreds of millions of dollars to Trump's company. The resignation of another longtime colleague of Vrablic, Dominic Scalzi, was also accepted by the bank, Hunter said, without mentioning the reason for the the coronavirus pandemic crisis shows no signs of easing, even if the vaccine is released on the market. It still faces severe social lockdown policies, with a number of states (such as California, Minnesota, and Michigan) forcing even tougher restrictions in this round than before. It's a big blow to the leisure industry that is still reeling from one of the toughest years in memory. With the difficulties facing restaurants getting more press, but in the cruise industry, Corona was the perfect storm. Before the pandemic, the cruise industry , which did business worth $150 billion a year, is expected to carry 32 million passengers in 2020. That's all in the past. During the summer, the industry staggered when more than 3,000 COVID cases were linked to 123 separate cruise ships and resulted in 34 deaths. After such a difficult year, it is useful to withdraw and give a snapshot of the state of the industry. JPMorgan analyst Brandt Montour has done just that with a comprehensive review of the cruise industry in general and three cruise line giants in particular. We believe cruise shares will continue to grind higher in the near future, driven overwhelmingly by the broader vaccine backdrop/progress. Looking further, market participants will face plenty of headwinds when it comes to restarting/ramping operations at 2Q3Q21, but significant sequential improvements in revenue/cash flows during this period are likely to dominate the narrative, and we believe investors will continue to look through the short-term failures of 2022 characterized by fully ramped capacity, near full-occupied, and rated manageable pricing pressures, Montour opined. In light of this, Montour has selected two stocks that are worth the risk, and one should be avoided by investors for the time being. Using tipranks stock comparison tool, we line up three side by side to make a lowdown on what short-term holds for those cruise line players. Royal Caribbean (RCL)The second largest cruise line, Royal Caribbean, remains the best pick for Montour and his company. The company has spent its resources on meeting the challenges of the pandemic and the challenges of the pandemic, releasing liquidity and simplifying and modernising the fleet. Maintaining liquidity was the most pressing issue. While the company continued with some cruisers and even took over the delivery of a new ship, the Silver Moon, most operations remained suspended. For Q3, the company reported adjusted revenue of -$5.62, below the consensus of -$5.17. Management estimates that cash burning is between $250 million and $290 million per month. To combat this, rcl reported $3.7 billion in liquidity at the end of September. This included $3 billion in cash on hand as well as $700 million available on a line of credit. At the end of q3, total liquidity Decreased by 9% in year 2. Since the third quarter ended, it ended, increased its cash position by more than $1 billion, issuing $500 million in senior notes and selling shares, bringing an additional 8.33 million shares on the market for $60. Montour writes in a letter about Royal Caribbean: [We] are the most constructive in the OW-rated RCL, which we believe has the most attractive demand leaders... its extensive investments in premium-priced new hardware as well as consumer data all define RCL well to outsize the industry's revenue ratios, margins and ROIC in the long term. Montour supports overweight (i.e. Buy) reviews with a $91 price target. This figure represents an upward potential of 30% by 2021. (To watch Montour's past, click here) Do the rest of the street agree? As it turns out, the analyst consensus is more of a mixed bag. 4 Buy reviews and cargo hold 6 give RCL moderate purchase status. Meanwhile, the stock is selling at $69.58 per share, slightly above its $68.22 average price target. (See RCL inventory analysis from TipRanks) Norwegian Cruise Line (NCLH) With a market cap of $7.45 billion and a fleet of 28 ships, Norwegian Cruise Line found it relatively smaller in size than an advantage in this pandemic time. With the smaller and newer fleet, overhead costs, especially the maintenance of ships, were lower. These benefits don't mean the company avoided the storm. Earlier this month, Norwegian announced that it would extend its road policy, which will be extended until 31 December 2021. These cancellations come as Norwegian revenues are down - in the third quarter, the top line is just $6.5 million, up from $1.9 billion in the quarter a year ago. The company also reported a $150 million-a-month cash burn. To burn cash and combat minimum revenues, The Norwegian took steps to improve liquidity in November and December. The company closed at $850 million, at 5.875%, and closed the stock issue in November 2026 and earlier this month. The stock offered a total of 40 million shares at $20.80 per share. Together, the two bids raised more than $1.6 billion in new capital. On the positive side, Norwegian is preparing for a possible restart of the full range of services. The company announced on December 7 that it had entered into a partnership with AtmosAir Solutions to deploy air purification systems on all 28 ships in the current fleet, using a screening technology known for defeating the coronavirus. JPM's Montour points out these benefits in his review of Norwegian, and summarizes the bottom line: This coupled with a relatively newer, higher-end, brand/ship footprint usually leads us to believe that we are well positioned to outperform pricing growth, although demographics skewed by older-age customers are likely to continue to drag on through 2021. Ultimately, the asset to the broader cruise industry, a higher beta of cruise recovery, and we need to see outperformance as the industry returns and investors are better off the risk spectrum. Montour gives the stock a $30 price target and overweight (i.e. Buy) rating. His goal is a 27% silver lining to the one-year time frame. Norwegian is another cruise line with a moderate buy in the analyst consensus. This rating is based on 4 purchases, 4 arresters and 1 sale set up in recent months. As RCL above, the stock price here, $23.55, is currently higher than the average price target, $23.22. (See NCLH inventory analysis from TipRanks) Carnival Corporation (CCL) Last up, Carnival, the world's largest cruise line, has a market cap of $23.25 billion, more than 100 ships across brands, and more than 700 destinations. In normal times, this huge footprint gave the company an advantage; now, however, it has become a costly burden. This is clear from the company's financial Q3 cash burn, which was close to $770 million. Like other major cruise companies, Carnival has extended the way cancellations, or from the company's point of view, to break operations. The Cunard line, one of carnival's brands, has cancelled trips to Queen Mary 2 and Queen Elizabeth through early June next year. Carnival also canceled operations in February at the ports of Miami, Galveston, and Port Canaveral, and pushed back the inaugor path of the new ship Mardi Gras at the end of April 2021. These measures have been taken in accordance with coronavirus restrictions. Carnival shares and revenues are suffering heavy losses this year. The stock is down 60% year-to-date, despite some recent price rallies since late October. Revenues fell by just $31 million in the fiscal third quarter, reported in September. Carnival reported a loss of nearly $3 billion that quarter. The company did not end the third quarter with more than $8 billion in available cash, an impressive resource to face in a difficult situation. This combination of strength and weakness led Montour to place a neutral (i.e. hold) rating on CCL shares. However, the $25 price target points to a 23% advantage. Montour wrote in his commentary on Carnival: [We believe] that due to the relative net returns seen in 2018-2019 due to its sheer size, the main thinking is likely to be on the other side of the crisis... However, given CCL's relative share discount, lower price growth before the crisis and geographical diversification, we see the company as the least downside over the next few months and not surprised by its recent performance. We believe this will turn around in 2H21. Overall, Carnival has a Lunar rating on the analyst consensus. This assessment is based on 10 reviews, broken down into 1 purchase, 8 hold and 1 sale. The stock is selling for $20.28 and the average price target represents a downside potential of ~7%. (See CCL file analysis by TipRanks) To find good ideas for stocks trading with attractive valuations, visit tipranks' best stocks buy, a newly launched tool that combines all of TipRanks equity insights. Disclaimer: The opinions in this article are exclusively those of the featured analysts. The content is for informational use only. It is very important to do your own analysis before making any investment. Reports of an Apple car shed light on QuantumScape, an emerging car battery manufacturer. Maker.